¶ Cerluten (Brain Bioregulator)
| Source | Natural Bovine Cerebral Cortex |
| Active Substance | Peptide Complex A-5 |
| Molecular Weight | < 10,000 Daltons (< 10 kDa) |
| Primary Class | Cytomax Bioregulator |
| Primary Mechanism | Epigenetic Modulation (Gene Transcription) |
| Administration | Oral (Capsules), Sublingual (Drops) |
| FDA Status | Unregulated Supplement (US/EU) |
Cerluten is an orally bioavailable natural peptide bioregulator belonging to the "Cytomax" class, derived from the cerebral cortex of young cattle [1][2]. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Cerluten serves as an epigenetic modulator designed to restore protein synthesis and normalize metabolic processes in the brain [3][4]. Unlike traditional synthetic nootropics that artificially force neurotransmitter release or neuronal firing, Cerluten functions as a biological "gene switch" to facilitate structural neuron repair, support cognitive reserve, and enhance endogenous neuroprotective pathways [5][6].
¶ At a Glance
¶ Key Points
- Targeted Cognitive Restoration: Specifically indicated for age-related cognitive decline, recovery from central nervous system (CNS) trauma (strokes, TBIs), and chronic cerebral circulatory disorders [1:1][3:1].
- Epigenetic Modification: Operates by binding directly to DNA promoter regions inside the neuronal cell nucleus, upregulating genes for neurotrophic factors (BDNF, NGF) and essential antioxidant enzymes (SOD2, GPX1) [3:2][7].
- Excellent Safety Profile: Exhibited no acute or chronic toxicity, side effects, or drug interactions in over 30 years of extensive clinical and gerontological use [8][6:1].
- Gradual, Satiating Benefits: Shows cumulative, slow-acting benefits. Rather than providing an immediate acute stimulant effect, it gradually reconstructs tissue, with therapeutic effects persisting for 3 to 6 months post-treatment [1:2][9].
¶ What People Use It For
- Cognitive Maintenance & Reserve: Preserving processing speed, focus, and memory during physiological aging.
- Stroke & TBI Rehabilitation: Promoting speech recovery (aphasia resolution) and reducing muscular spasticity post-trauma [1:3][10].
- Cerebral Encephalopathy Management: Mitigating headache intensity, attention oscillations, and fatigue associated with vascular brain diseases [1:4][3:3].
¶ Safety & Status
Exhibits no known clinical toxicity or drug interactions. Standard caution is advised for pregnant/lactating populations due to a lack of dedicated trials. As an animal-extracted complex, it is not vegan or vegetarian.
- US and EU Status: Unregulated dietary supplement. It cannot be legally marketed as a drug to treat, prevent, or cure specific diseases, but is widely available as a research chemical or health supplement.
- Russian Regulatory Status: Approved as a parapharmaceutical (food supplement/bioregulator) and widely utilized in anti-aging, military, and sports medicine protocols.
¶ Protocol & Dosage
Note: The protocols below are based on clinical trials conducted by the St. Petersburg Institute of Bioregulation and Gerontology. This information is for clinical reference and educational purposes only.
¶ Standard Protocols
- Standard Anti-Aging & Preventative Protocol:
- Dose: 1–2 capsules (10–20 mg of active Peptide Complex A-5) daily [1:5][7:1].
- Timing: Take once daily, 15–20 minutes before breakfast on an empty stomach.
- Duration: A single course of 10 to 20 days (requiring 20 to 40 capsules) [1:6][10:1].
- Frequency: Repeat the course every 3 to 6 months [1:7][7:2].
- Intensive Therapeutic Protocol (Post-Stroke, Post-TBI, Severe Cognitive Decline):
- Sublingual (Lingual) Protocol:
¶ Reconstitution & Storage
- Storage (Capsules): Highly stable at room temperature. Store in a cool, dry place away from direct sunlight.
- Storage (Sublingual Drops): Refrigerate (2–8°C / 36–46°F) after opening. Do not freeze. Ensure the dropper remains sterile to avoid contamination.
¶ Contextual Narrative
¶ The "Why": Epigenetic Restoration over Psychostimulation
Mainstream pharmacological cognitive enhancers (such as methylphenidate, modafinil, or caffeine) primarily operate by blocking neurotransmitter reuptake (dopamine, norepinephrine) or forcing neuronal firing. While effective for temporary focus, they impose a metabolically taxing drain on brain cells, often causing tolerance, receptor downregulation, and subsequent cognitive "crashes."
Cerluten takes a fundamentally different therapeutic approach based on Vladimir Khavinson's Peptide Regulation of Aging Theory [13][4:1]. The central premise of this theory is that aging, trauma, and disease are characterized by the progressive silencing of gene expression, which severely restricts cellular protein synthesis [3:4][13:1]. By re-introducing low-molecular-weight brain signal peptides, Cerluten "unfolds" chromatin structures, allowing RNA polymerase to access crucial gene sequences [3:5][13:2]. This triggers the endogenous synthesis of structural proteins, repair factors, and neural enzymes, regenerating tissue and expanding "brain reserve margin" sustainably [3:6][7:4].
¶ Reality Check: Managing Expectations
- The Sensation: Cerluten does not provide an immediate cognitive high, euphoria, or acute focus boost. Users looking for a "work-study" stimulant will likely feel nothing in the first few days of use.
- The Timeline: Benefits manifest subtly, usually appearing toward the end of a 10-day cycle or in the weeks following completion. Users typically report a gradual clearing of chronic brain fog, stabilized emotional lability, improved verbal recall, and sustained mental stamina.
- Bioavailability and Variances: Because Peptide Complex A-5 is a natural extraction from bovine cerebral tissue, it contains a diverse spectrum of synergistic micro-peptides [1:10][3:7]. This biological complexity makes its therapeutic action broader but less predictable compared to isolated synthetic single-peptide analogs like Pinealon.
¶ Sourcing & Commercial Context
Cerluten is manufactured and distributed under the brand names Cytomax (capsules) and Lingual (sublingual drops).
- Purity Concerns: Because it is an animal-derived product, sourcing from authorized, reputable distributors is critical to ensure proper bovine pathogen screening (e.g., ensuring herds are certified free of Bovine Spongiform Encephalopathy / BSE).
- Natural vs. Synthetic: Pinealon (Glu-Asp-Arg) is the synthetic tripeptide version containing the primary active sequence of the brain cortex [3:8][6:2]. It is faster acting and cheaper to produce, but lacks the broad, multi-peptide complexity found in the natural Cerluten extract [1:11][3:9].
¶ Mechanism of Action
¶ Epigenetic Switching & Transcriptional Initiation
The peptides within Cerluten cross the blood-brain barrier (BBB) and enter the neuronal cytoplasm via proton-coupled oligopeptide transporters (POTs) [3:10][4:2]. Once inside the nucleus, they interact with the genome through a multi-step epigenetic cascade:
- Direct DNA Binding: These short-chain peptides bind selectively to promoter regions of DNA double helices and associate with basic histone proteins (H1, H2B, H3, H4) [3:11][7:5].
- Chromatin Remodeling: This physical binding induces conformational changes, relaxing and "unfolding" tightly wound heterochromatin into transcriptionally active euchromatin [7:6][13:3].
- Upregulating Protein Expression: RNA polymerase gains access to the newly exposed genes, initiating transcription of mRNA and subsequent ribosomal translation of critical neuroprotective proteins [3:12][7:7].
¶ Specific Molecular & Gene Targets
Research demonstrates that the Peptide Complex A-5 upregulates several key neurobiological markers:
- Neurotrophic Factors (BDNF and NGF): Stimulates expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), crucial for synaptic plasticity, neurogenesis, and long-term potentiation [3:13].
- Endogenous Antioxidant Enzymes: Significantly increases transcription of mitochondrial Superoxide Dismutase 2 (SOD2), Glutathione Peroxidase 1 (GPX1), and Catalase [3:14][7:8]. This neutralizes reactive oxygen species (ROS) and mitigates lipid and protein peroxidation in the cerebral cortex [1:12][3:15].
- Neuronal Regeneration & Cytoskeleton Structure: Upregulates markers of structural repair including Nestin (neural stem cell marker), GAP43 (axonal growth cone development), and β-tubulin III (neuronal microtubule component) [3:16].
¶ Clinical Research & Human Evidence
Note: The bulk of clinical research on Cerluten originates from Russian scientific institutes, Northwest Branch of the Russian Academy of Medical Sciences, and clinical trials sponsored by Khavinson's laboratory. High-level, independent Western Phase III trials are currently absent.
¶ The 48-Patient CNS Pathology Trial (St. Petersburg, 2003–2004)
The primary clinical cornerstone validating Cerluten is a controlled trial conducted at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology [1:13][10:3].
¶ Cohort & Inclusion Criteria
- Intervention Group: 48 patients (varying ages, disease duration 1 to 10 years) receiving Cerluten [1:14][10:4].
- Control Group: 37 patients receiving standard-of-care baseline therapies [1:15][10:5].
- Diagnostic Profile: Patients with chronic cerebrovascular insufficiency (vascular encephalopathy), post-stroke sequelae (sensory/motor aphasia, muscular spasticity), and long-term traumatic brain injury (TBI) deficits [1:16][10:6].
- Administration: 1–2 capsules of Cerluten, 2–3 times daily (10–20 mg of A-5 complex per dose), taken 10–15 minutes before meals for 10 to 20 days [1:17][10:7].
¶ Psychometric Assessment: The Bourdon Correction Task (Proofreading Test)
To objectively quantify attention span, concentration capacity, and mental fatigability, researchers utilized the Bourdon Correction Task [1:18][10:8]:
- Methodology: Patients scanned dense sheets of symbols, crossing out specified target characters within strict time-restricted intervals.
- Results: The Cerluten intervention group processed a significantly higher total number of characters (processing speed) and committed far fewer errors (increased accuracy) [1:19][10:9].
- Attention Oscillations: The performance curves of treated patients showed flat, stable, and gradual declines, indicating a reduction in rapid, pathological attention oscillations and chronic fatigability, while control patients exhibited erratic attention drops [1:20][10:10].
¶ Objective Physiological Measure: Electroencephalography (EEG)
To confirm structural modifications in cortical activity, visual and quantitative EEG analysis was performed [1:21][10:11]:
- Baseline state: Prior to administration, patients exhibited disorganized EEG profiles (Types III, IV, and V) characterized by suppressed alpha rhythms and high slow-wave activity (delta/theta waves), indicative of cerebral ischemia or structural stress [1:22][10:12].
- Post-Treatment: Cerluten administration resulted in the normalization of cortical bioelectrical activity. This was characterized by a highly significant enhancement of the alpha-index (stabilizing alpha-wave rhythmicity), which correlates with alert relaxation, reduced neural stress, and improved sensory-motor processing [1:23][10:13].
¶ General Clinical Outcomes
- Efficacy Rating: A "good" (highly significant) clinical recovery was recorded in 64.6% of patients in the Cerluten group compared to only 27.0% in the control group [1:24][10:14].
- Subjective Complaints: Chronic headaches and sleep disturbances dropped 2- to 3-fold. Subjective complaints of severe memory impairment, brain fog, and absent-mindedness dropped precipitously from 48.7% of the cohort down to 14.6% [1:25][10:15].
- Motor & Speech Deficits: Patients recovering from stroke displayed moderate regression of focal deficits, showing improved speech fluency (aphasia resolution) and diminished muscular spasticity [1:26][10:16].
¶ Geroprotective & Aging Studies
In long-term clinical monitoring of elderly populations (60–74 years) displaying accelerated physiological aging of the central nervous system, periodic courses of Cerluten resulted in improved emotional stability, preserved processing speed, and decreased markers of biological brain age [3:17][13:4].
¶ Evidence Summary Table (Human Outcomes)
| Outcome / Goal | Effect | Consistency | Evidence Quality | Trials / Cohort | Notes (Population, Duration, Dose) |
|---|---|---|---|---|---|
| Attention & Focus (Correction Task) | High | Low to Moderate (Russian clinical trials) | Controlled trial, 48 patients in treatment group | 10–20 mg of A-5 daily for 10–20 days. Significantly increased characters processed, decreased error rate, and resolved attention oscillations [1:27][10:17]. | |
| Speech Recovery (Aphasia) | Moderate | Low | Clinical trial, subset of stroke patients | Post-stroke motor and sensory aphasia displayed moderate regression of deficits as an adjunct [1:28][10:18]. | |
| Motor Recovery (Spasticity) | Moderate | Low | Clinical trial, subset of TBI & stroke patients | Reduced spastic muscle tone and improved focal motor symptoms alongside standard therapy [1:29][10:19]. | |
| Cerebral Bioelectrical Activity (EEG) | High | Low to Moderate | Sub-cohort of 48-patient trial | Normalization of alpha-rhythm index, suppression of pathological slow-wave types [1:30][10:20]. | |
| Symptom Deficit Reduction | High | Low to Moderate | Controlled trial, 48 patients | Memory complaints decreased from 48.7% to 14.6%. Headaches and sleep disturbances reduced 3-fold [1:31][10:21]. | |
| Cognitive Maintenance (Geriatric) | High | Low to Moderate | Geriatric monitoring cohorts | Periodic courses (every 3-6 months) slow age-related decline of CNS reserves [3:18][13:5]. |
¶ Comparisons: Cerluten vs. Other Brain Peptides
| Feature | Cerluten (A-5) | Pinealon | Cortexin | Cerebrolysin |
|---|---|---|---|---|
| Type | Natural Complex (Cytomax) | Synthetic Tripeptide (Cytogen) | Natural Complex Drug | Natural Complex Hydrolysate |
| Active Sequence | Complex A-5 | Glu-Asp-Arg (EDR) | Purified Neuropeptides | Porcine Brain Peptides & Amino Acids |
| Route of Admin | Oral (Capsules) / Sublingual | Oral / Sublingual / Injection | Intramuscular (IM) Only | Intravenous (IV) / IM Only |
| Onset of Action | Slow (Weeks, Cumulative) | Fast (Hours to Days) | Fast | Fast |
| Duration of Effect | Long (3–6 months post-cycle) | Short (Cessation-dependent) | Medium/Long | Medium |
| Evidence Level | Tier 3 (Russian trials) [1:32][10:22] | Tier 3 (Russian trials) [6:3][12:1] | Tier 2 (National guidelines) [3:19][12:2] | Tier 1 (Systematic Reviews) [14][15] |
| Key Advantage | High convenience (oral) and broad multi-peptide synergy [1:33][3:20]. | Rapid cognitive activation; easily synthesized and cost-effective [6:4][12:3]. | Robust clinical data for acute TBI and pediatric encephalopathies [15:1][12:4]. | Gold standard for acute stroke & Alzheimer’s disease [14:1][15:2]. |
¶ Safety, Toxicology & Contraindications
¶ Toxicology Profile
- Acute Toxicity: Animal safety models show that single doses exceeding standard therapeutic levels by 1,000-fold failed to induce any metabolic, histopathological, or behavioral toxicity [1:34].
- Chronic Toxicity: Continuous long-term administration reveals no tissue degeneration, mutagenic effects, chromosomal aberrations, or drug dependence [1:35][8:1].
- Withdrawal Syndrome: Cessation of Cerluten is entirely asymptomatic; no rebound brain fog or neurological withdrawal has been documented [1:36][10:23].
¶ Side Effects
- Incidence: Extremely rare. No significant systemic side effects have been reported in over three decades of clinical application [8:2][13:6].
- Minor Reactivity: Extremely rare mild hypersensitivity reactions (skin rash, transient headache) may occur, usually linked to inactive ingredients in the capsule shell (e.g., gelatin or lactose).
¶ Contraindications
- Pregnancy & Lactation: Standard preventative exclusion. Due to the complete absence of clinical safety data in pregnant or breastfeeding women, use is strictly contraindicated [8:3][11:1].
- Bovine Allergy/Intolerance: Hypersensitivity to bovine-derived biological proteins.
¶ Peptide Stacking
Bioregulator protocols heavily emphasize synergistic organ stacking to enhance systemic outcomes.
- The Neuro-Vascular "Triad" Stack:
- The Neuro-Endocrine Longevity Stack (The Khavinson "Gold Standard"):
¶ References
https://www.antiaging-systems.com/articles/report-on-the-results-of-clinical-study-of-peptide-bioregulator-cerluten/ Antiaging Systems. (n.d.). Report on the Results of Clinical Study of Peptide Bioregulator Cerluten. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://vita-stream.com/a-5-cerluten-brain-peptide-bioregulator/ Vita Stream. Cerluten A-5: Natural Support for Brain Health. ↩︎
https://biolongevitylabs.com/research/cerluten-peptide-bioregulator/ BioLongevity Labs. (2025). Cerluten Peptide Bioregulator Research. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://khavinson.info/downloads/ibg.pdf Khavinson, V. K. St. Petersburg Institute of Bioregulation and Gerontology Report. ↩︎ ↩︎ ↩︎
https://www.reddit.com/r/Peptides/comments/nkj7jq/peptides_for_cognition/ Reddit. (2021). Peptides for Cognition. ↩︎
https://research.peptidescienceinstitute.com/pinealon-1 Peptide Science Institute. (2025). Pinealon: The Ultimate Cognitive Enhancer. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://qisupplements.com/blogs/news/clinical-studies-of-the-effect-of-cerluten-on-the-brain-and-nervous-system QI Supplements. (2018). Clinical studies of the effect of Cerluten on the brain and nervous system. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://cosmicnootropic.com/products/cerluten-bioregulator/ Cosmic Nootropic. (n.d.). Cerluten Bioregulator. ↩︎ ↩︎ ↩︎ ↩︎
https://peptidr.com/2021/11/09/bioregulators/ Peptidr. (2021). Peptides for Cognition. ↩︎
https://peptidi.net/en/clinical-study-of-cerluten Peptidi.net. Clinical study of Cerluten. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://qisupplements.com/products/a-5-cerluten-lingual-natural-sublingual-brain-peptide-complex QI Supplements. A-5 Cerluten Lingual Natural Sublingual Brain Peptide Complex. ↩︎ ↩︎
https://peptides4.com/wp-content/uploads/2025/02/Catalog_2022_first-part-ENG-web.pdf Peptides Company. (2022). Product Catalog 2022: Peptide Complex A-5. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://pmr.cuni.cz/file/5636/pmr_supplement_113-2012.pdf Khavinson, V., et al. (2012). Application of peptide geroprotectors in elderly patients with age-related pathology. Prague Medical Report. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
https://pmc.ncbi.nlm.nih.gov/articles/PMC11080511/ Havas, D., et al. (2024). Comparing the biological activity and composition of Cerebrolysin with other peptide preparations. Journal of Medicine and Life. ↩︎ ↩︎
https://geropharm.com/upload/iblock/685/Comparison of Behavioral Effects of Cortexin and Cerebrolysin Injected into Brain Ventricles.pdf Geropharm. Comparison of Behavioral Effects of Cortexin and Cerebrolysin. ↩︎ ↩︎ ↩︎